Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
12:23am, Friday, 31'st Jul 2026
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
07:06pm, Thursday, 30'th Jul 2026
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Veracyte Announces Second Quarter 2026 Financial Results
04:05pm, Thursday, 30'th Jul 2026
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SO
Veracyte to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 28'th Jul 2026
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following inves
First Trust Advisors LP Buys 833,543 Shares of Veracyte, Inc. $VCYT
03:53am, Sunday, 26'th Jul 2026
First Trust Advisors LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 64.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
11:06am, Thursday, 23'rd Jul 2026
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
08:15am, Thursday, 23'rd Jul 2026
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Fifth Third Bancorp Purchases 52,043 Shares of Veracyte, Inc. $VCYT
04:07am, Thursday, 23'rd Jul 2026
Fifth Third Bancorp boosted its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 10,285.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
07:57am, Tuesday, 21'st Jul 2026
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Amova Asset Management Americas Inc. Has $33.63 Million Holdings in Veracyte, Inc. $VCYT
03:16am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.9% in the undefined quarter, according to the company in its most recent 13F filing with the SE
Artisan Mid Cap Fund Q2 2026 Performance Review
01:56pm, Wednesday, 15'th Jul 2026
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple p
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
06:59am, Wednesday, 15'th Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
04:05pm, Thursday, 09'th Jul 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 af
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
01:01pm, Wednesday, 08'th Jul 2026
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
09:05am, Saturday, 04'th Jul 2026
Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced dire
